studija o gmo vijeće za gmo 2013 - Ministarstvo zdravlja

5. Ganges, L., M. Barrera, J.I. Núñez, I. Blanco, M.T. Frias, F. Rodríguez, F. Sobrino(2005): A DNA vaccine expressing the E2 protein of classical swine fever virus elicitsT cell responses that can prime for rapid antibody production and confer totalprotection upon viral challenge. Vaccine 23, 3741-52.6. Greiser-Wilke, I., V. Moennig (2004): Vaccination against classical swine fever virus:limitations and new strategies. Animal Health Research Reviews 5, 223-226.7. Hulst, M.M:, D.F. Westra, G. Wensvoort, R.J.M. Moormann (1993): Glycoprotein E1of hog cholera virus expresed in insect cells protects swine from hog cholera. Journalof Virology 67, 5435-5447.8. Hulst, M.M., G. Himes, E. Newbigin, R.J.M. Moormann (1994): Glycoprotein E1 ofhog cholera virus expression in insect cells and identificationas a ribonuclease.Virology, 200, 558-565.9. Meeusen, E.N.T., J. Walker, A. Peters, P-P. Pastoret, G. Jungersen (2007): Currentstatus of veterinary vaccines. Clinical microbiological rewievs 20, 489-510.10. OIE Terrestrial Manual (2008): Principles of veterinary Vaccine production. Chapter1.1.8, 90-104.11. Shams, H. (2005): Recent developments in veterinary vaccinology. The veterinaryJournal 170, 289-299.12. Spier, R.E. (1996): International meeting on the nucleic acid vaccines for theprevention of infectious disease and regulating, nucleic acid (DNA) vaccines. Vaccine13, 1285-1288.13. Directive 2001/82 EC14. Directive 2004/28 EC15. Directive 2001/18/EC (Annex II).16. Voigt, H., C. Merant, D. Wienhold, A. Braun, E. Hutet, M.F. Le Potier, A.Saalmüller,e. Pfaff, M. Büttner (2007): Efficient priming against classical swine fever with a safeglycoprotein E2 expressing Orf virus recombinant (ORFV VrV-E2). Vaccine 25, 915-26.